- Home
- SWVL vs FBIO Comparison
SWVL vs FBIO Comparison
Compare SWVL & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWVL
- FBIO
- Stock Information
- Founded
- SWVL 2017
- FBIO 2006
- Country
- SWVL United Arab Emirates
- FBIO United States
- Employees
- SWVL N/A
- FBIO N/A
- Industry
- SWVL Business Services
- FBIO Biotechnology: Pharmaceutical Preparations
- Sector
- SWVL Consumer Discretionary
- FBIO Health Care
- Exchange
- SWVL Nasdaq
- FBIO Nasdaq
- Market Cap
- SWVL 44.5M
- FBIO 49.1M
- IPO Year
- SWVL N/A
- FBIO N/A
- Fundamental
- Price
- SWVL $4.79
- FBIO $1.95
- Analyst Decision
- SWVL
- FBIO Strong Buy
- Analyst Count
- SWVL 0
- FBIO 2
- Target Price
- SWVL N/A
- FBIO $21.00
- AVG Volume (30 Days)
- SWVL 22.8K
- FBIO 217.9K
- Earning Date
- SWVL 07-22-2025
- FBIO 08-12-2025
- Dividend Yield
- SWVL N/A
- FBIO N/A
- EPS Growth
- SWVL N/A
- FBIO N/A
- EPS
- SWVL N/A
- FBIO N/A
- Revenue
- SWVL $17,207,362.00
- FBIO $57,784,000.00
- Revenue This Year
- SWVL N/A
- FBIO $51.59
- Revenue Next Year
- SWVL N/A
- FBIO $44.74
- P/E Ratio
- SWVL N/A
- FBIO N/A
- Revenue Growth
- SWVL N/A
- FBIO N/A
- 52 Week Low
- SWVL $2.40
- FBIO $1.33
- 52 Week High
- SWVL $8.05
- FBIO $2.89
- Technical
- Relative Strength Index (RSI)
- SWVL 64.82
- FBIO 55.10
- Support Level
- SWVL $4.08
- FBIO $1.81
- Resistance Level
- SWVL $4.89
- FBIO $2.03
- Average True Range (ATR)
- SWVL 0.47
- FBIO 0.11
- MACD
- SWVL 0.07
- FBIO 0.01
- Stochastic Oscillator
- SWVL 91.60
- FBIO 65.63
About SWVL Swvl Holdings Corp
Swvl Holdings Corp is a technology-driven mobility company that aims to provide reliable, safe, cost-effective and environmentally responsible mass transit solutions. It provides mobility solutions for enterprises and government and individual commuters across-multiple markets with clients such as Amazon, Bosch, E&, P&G and Siemens. The Company operates in Egypt, Saudi Arabia and the UAE.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.